Built by operators, for operators

Sharon is a seasoned commercial leader and launch architect across diabetes, obesity, and advanced metabolic therapies. One of the firm's earliest leaders, she spent five years helping build Echelon's commercial and field-execution capabilities, including the first cross-functional launch squads and the original playbooks for field team design and KOL engagement. She then spent four years at Amplity Health as National Sales Director, leading high-performing field and hybrid teams for top-100 pharma and biotech clients. Sharon recently rejoined Echelon as Senior Consultant, focusing on metabolic launch and retention strategy, field coaching, and talent evaluation.

Luis focuses on field force design, deployment, and performance management for complex specialty and metabolic launches. Over 16 years in pharma and biotech, he has held district and regional leadership roles with top-50 companies and a global contract commercialization firm, leading launches in diabetes, respiratory, and immunology. Luis joined Echelon in 2019 and specializes in translating launch blueprints into workable territory designs, incentive structures, and day-to-day field execution plans.

Hiroko supports EU and Asia-based clients in structuring U.S. entry models, including proxy offices, partnership structures, and phased field build-outs. She has 17 years of experience in commercial strategy and alliance management for top-50 pharma and large biotechs, with particular depth in Japan-US and EU-US collaboration models. Hiroko joined Echelon in 2022 from a major biopharma where she led cross-border launch initiatives in metabolic and oncology.

Chris works with clients on payer, distribution, and channel strategies that support both access and persistence for advanced metabolic and obesity therapies. With 18 years in market access and trade/channel roles at large pharma and specialty distributors, he has guided multiple GLP-1 and cardio-metabolic launches through complex PBM and specialty pharmacy landscapes. Chris joined Echelon in 2015 and leads many of the firm's payer-facing workstreams.

Marisol leads Echelon's training and new-manager coaching programs, with a focus on first-time leaders in metabolic and specialty franchises. Over 15 years, she has served as a specialty sales leader and commercial training director at two top-25 pharma companies, developing curricula for GLP-1, obesity, and cardiovascular launches. She joined Echelon in 2021 and designs practical, field-tested programs that support launch execution and retention initiatives.

Jing partners with Diego and client HEOR teams to ensure real-world insights inform launch and retention strategy. She has 16 years of experience in RWE and outcomes research roles across top-50 pharma and a global CRO, with a portfolio that includes diabetes, obesity, and cardiovascular programs. Jing joined Echelon in 2020 and is known for translating complex data into clear, commercially relevant recommendations.

Priya focuses on omnichannel design and patient experience programs that support adherence and engagement. Over 15 years in commercial and digital roles at large pharma and a leading digital health company, she has built HCP and patient journeys for GLP-1, cardio-renal, and autoimmune launches. She joined Echelon in 2018 and works closely with Sophia and Diego to integrate clinical, digital, and access levers into cohesive Retention Engines.

Danny advises on commercial and field-facing design that is compliant with evolving U.S. regulations in pharma and biotech. With 17 years in compliance and commercial operations roles across two top-20 pharma companies and a large contract commercialization firm, he has supported multiple high-visibility metabolic and specialty launches. Danny joined Echelon in 2016 and helps clients build programs that are both commercially effective and audit-ready.

Bella specializes in portfolio strategy and lifecycle planning for cardiometabolic and obesity franchises. She brings 15 years of experience in brand management and lifecycle strategy at top-50 pharma companies, working across diabetes, lipid, heart failure, and obesity assets. Bella joined Echelon in 2020 after leading cross-indication strategy for a major cardiometabolic portfolio.

Marcus supports clients in building field performance dashboards, incentive models, and territory optimization approaches that align with launch and retention goals. With 16 years in commercial analytics and sales operations roles at large pharma and a top-tier analytics vendor, he has supported multiple GLP-1 and specialty launches. Marcus joined Echelon in 2017 and is known for turning complex data into simple, actionable tools for field leaders.

Yuki focuses on alignment between medical affairs and commercial teams in advanced metabolic and specialty launches. She has 15 years of experience spanning medical affairs operations, MSL team coordination, and commercial collaboration at global pharma and biotechs. Yuki joined Echelon in 2019 and helps clients design compliant, effective touchpoints between field medical, sales, and market access.

Claudia designs and optimizes nurse liaison and patient support models that underpin adherence and persistence for metabolic and specialty therapies. A registered nurse with 17 years of experience in diabetes and cardiovascular programs, she has led clinical education and patient services teams at top-50 pharma companies and national hubs. Claudia joined Echelon in 2022 and works closely with Sophia on clinical-grade patient journey and support designs.

Ethan brings 15 years of experience in commercial finance and forecasting for pharma and biotech, including multiple metabolic and specialty launches. He has worked at two top-25 pharma companies and a major consulting firm, focusing on launch forecasting, scenario planning, and investment prioritization. Ethan joined Echelon in 2018 and helps clients quantify the economic impact of launch and retention decisions.

Naomi focuses on pricing, contracting, and value communication strategies for advanced metabolic and specialty products. With 16 years in pricing and market access roles at global pharma and a leading HEOR consultancy, she has guided several GLP-1 and obesity therapies through complex payer negotiations. Naomi joined Echelon in 2021 and supports clients in aligning price, access, and outcomes narratives.

Rafa designs KOL engagement and speaker program strategies that are clinically credible and commercially effective. He brings 15 years of experience in professional education and medical marketing roles at top-50 pharma companies, with significant work in diabetes, obesity, and cardiovascular spaces. Rafa joined Echelon in 2019 and helps clients identify and activate the right thought leaders while maintaining compliance and scientific integrity.

Emily focuses on organizational readiness and change management for first-time or high-stakes launches. With 17 years in commercial effectiveness and org development roles at large pharma and a global consultancy, she has led launch readiness and change programs across metabolic, oncology, and immunology portfolios. Emily joined Echelon in 2016 and helps clients align structure, governance, and behaviors to launch ambitions.